Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13271240 | 0.79 | CCR1 (0.48) | ALDH1A1CYP1A2HPGDHSD17B10 | |
| SCHEMBL13348672 | 0.73 | ALDH1A1 (0.42) | ALDH1A1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL13313419 | 0.71 | POLB (0.35) | — | |
| SCHEMBL13348670 | 0.70 | ALDH1A1 (0.33) | ALDH1A1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL13271296 | 0.68 | KDM4E (0.50) | ALDH1A1 | |
| SCHEMBL13313421 | 0.68 | CCR1 (0.35) | — | |
| SCHEMBL13271293 | 0.68 | CCR1 (0.53) | ALDH1A1 | |
| SCHEMBL13348638 | 0.64 | MAP4K4 (0.31) | ALDH1A1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL30557034 | 0.64 | MMP2 (0.48) | ALDH1A1CYP3A4ALOX12HIF1A | |
| SCHEMBL13818448 | 0.61 | RAB9A (0.50) | ALDH1A1CYP1A2CYP2C9HPGDCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-24 | — | — | US | disclosed |
| US-7692011-B2 | 8-hydroxy and 8-mercapto quinazolinones | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | ACHE, PSEN1, PSEN2 | ALDH1A1 703/4885CYP1A2 1906/4885CYP3A4 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.